Print  |  Close

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement


Active: No
Cancer Type: Melanoma NCT ID: NCT04543188
Trial Phases: Phase I Protocol IDs: C4471001 (primary)
NCI-2020-08201
Eligibility: 16 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Pfizer Inc
NCI Full Details: http://clinicaltrials.gov/show/NCT04543188

Summary

First-in-human study to assess safety, tolerability, PK, and preliminary activity of
PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF
V600-mutated advanced solid tumor malignancies with and without brain involvement.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.